Patient costs of hypertension care in public health care facilities in Kenya

Robinson Oyando\textsuperscript{1} \textsuperscript{\textdagger} | Martin Njoroge\textsuperscript{1} | Peter Nguhu\textsuperscript{1} | Fredrick Kirui\textsuperscript{2} | Jane Mbut\textsuperscript{2} | Antipa Sigilai\textsuperscript{3} | Zipporah Bukania\textsuperscript{4} | Andrew Obala\textsuperscript{5} | Kenneth Munye\textsuperscript{1} | Anthony Etyang\textsuperscript{3} | Edwine Barasa\textsuperscript{1,6}

\textsuperscript{1}Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya
\textsuperscript{2}Clinical Unit, KEMRI Centre for Clinical Research, Nairobi, Kenya
\textsuperscript{3}Epidemiology and Demography, KEMRI Centre for Geographic Medicine Research, Coast, Kilifi, Kenya
\textsuperscript{4}Public health nutrition, maternal and child health unit, KEMRI Centre for Public Health Research, Nairobi, Kenya
\textsuperscript{5}Medical Microbiology and Parasitology, Moi University, Eldoret, Kenya
\textsuperscript{6}Nuffield Department of Medicine, University of Oxford, Oxford, UK

Correspondence
Robinson Oyando, Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, PO Box 43640-00100, Nairobi, Kenya.
Email: royando@kemri-wellcome.org

Funding information
KEMRI Internal Research Grant, Grant/Award Number: KEMRI IRG-04; Wellcome Trust International Master’s Fellowship, Grant/Award Number: 214622; Wellcome Trust core grant, Grant/Award Number: 092654; Research Training Fellowship, Grant/Award Number: 107527

Summary

Background: Hypertension in low- and middle-income countries, including Kenya, is of economic importance due to its increasing prevalence and its potential to present an economic burden to households. In this study, we examined the patient costs associated with obtaining care for hypertension in public health care facilities in Kenya.

Methods: We conducted a cross-sectional study among adult respondents above 18 years of age, with at least 6 months of treatment in two counties. A total of 212 patients seeking hypertension care at five public facilities were interviewed, and information on care seeking and the associated costs was obtained. We computed both annual direct and indirect costs borne by these patients.

Results: Overall, the mean annual direct cost to patients was US$ 304.8 (95% CI, 235.7-374.0). Medicines (mean annual cost, US$ 168.9; 95% CI, 132.5-205.4), transport (mean annual cost, US$ 126.7; 95% CI, 77.6-175.9), and user charges (mean annual cost, US$ 57.7; 95% CI, 43.7-71.6) were the highest direct cost categories. Overall mean annual indirect cost was US$ 171.7 (95% CI, 152.8-190.5). The incidence of catastrophic health care costs was 43.3% (95% CI, 36.8-50.2) and increased to 59.0% (95% CI, 52.2-65.4) when transport costs were included.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2019 The Authors The International Journal of Health Planning and Management Published by John Wiley & Sons Ltd
Conclusions: Hypertensive patients incur substantial direct and indirect costs. High rates of catastrophic costs illustrate the urgency of improving financial risk protection for these patients and strengthening primary care to ensure affordability of hypertension care.

KEYWORDS
Catastrophic costs, hypertension, Kenya

1 | BACKGROUND

The goal of universal health coverage (UHC) is to ensure that everyone has access to quality health care services they need without the risk of financial hardship.\textsuperscript{1,2} Financial protection against the cost of illness is therefore a key policy objective of UHC.\textsuperscript{3} The double burden of communicable and noncommunicable diseases (NCDs) in many low- and middle-income countries (LMICs) places an additional burden on the already constrained health resources and is a threat to the attainment of UHC goals.\textsuperscript{4-7}

Kenya is committed towards attaining UHC by 2022.\textsuperscript{8} The Kenyan health sector is funded by different sources\textsuperscript{9} including; the government, out-of-pocket payments (OOP) and donors.\textsuperscript{10-14} The high level of OOP payments increases the risk of catastrophic health expenditure where households spend a large proportion of their budget on health care, which consequently have negative implications on living standards as they forego other goods and services.\textsuperscript{15} The incidence of catastrophic health care expenditure (at the 40% of annual non-food expenditure threshold) related to direct health care payments to providers in Kenya is estimated to be 4.52%.\textsuperscript{16} In addition, it has been shown that households with a member with an NCD are two times more likely to incur catastrophic health expenditure compared with households where no member has an NCD.\textsuperscript{16} A minority of individuals (19%) in Kenya have health insurance coverage,\textsuperscript{17} and almost all employees in the formal sector, which is less than one-fifth of those employed, are covered through the National Hospital Insurance Fund (NHIF).\textsuperscript{18,19}

Several studies done in Kenya have identified a high prevalence of hypertension (ranging from 12.3% to 50.1%).\textsuperscript{5,20,21} Examining the costs incurred by patients to access hypertension care is necessary as evidence suggests they are a barrier to access.\textsuperscript{22,23} Knowledge of such costs is limited in Kenya. The objective of this study was to determine the costs associated with accessing hypertension care from the patient perspective.

2 | METHODS

2.1 | Study setting

The study was conducted from June to December 2017 in two sites in Kenya (Kilifi and Bungoma counties) purposively selected to reflect a diverse set of demographic, socio-economic, and geographical settings. Kilifi is located on the coast of Kenya, and a high burden of stroke and heart failure has been described in this area.\textsuperscript{24} The population in Kilifi has been well characterized by data from the health and demographic surveillance system run by the KEMRI Wellcome Trust Research Programme.\textsuperscript{25} The Webuye Health and Demographic Surveillance System run by Moi University is located in Bungoma County in the western region of Kenya.\textsuperscript{26} Multiple cardiovascular risk factors have been identified in this area.\textsuperscript{27} This was part of a larger study that assessed the health system performance and the
capacity for effective coverage of diabetes mellitus and hypertension services at primary care in the context of a devolved health system (KEMRI Scientific Ethics and Review Unit protocol number 3270).

Six public health care facilities were purposively selected in consultation with county health officials to generate a sample of facilities with different workloads, plus the location of the clinics relative to the communities served. However, due to the nationwide nurses’ strike at the time of data collection, 28 data were collected from five facilities unlike the anticipated six facilities in the two counties. In Kilifi, a public hospital and a health centre that provided hypertension treatment were selected while in Webuye, three public hospitals were sampled. For this descriptive analysis, data from all the facilities were pooled.

2.2 | Sample size and sampling
The target enrolment was 278 patients for a sample size sufficient to obtain a precise estimate of hypertension patient costs based on the formulae by Kirkwood:

\[
N = (Z_{\alpha/2} + Z_\beta)^2 \left( \frac{P(1-P)}{e^2} \right)
\]

where

- \(Z_{\alpha/2}\) is the critical value of the normal distribution at \(\alpha/2\) (for a confidence level of 95%, \(\alpha\) is 0.05 and the critical value is 1.96)
- \(Z_\beta\) is the critical value of the normal distribution at \(\beta\) (for a power of 80%, \(\beta\) is 0.2 and the critical value is 0.84)
- \(P\) is the expected true proportion of hypertension in the population in Kenya of 15% (0.15)
- \(e\) is the desired standard size of standard error around the estimated proportion of 6% (+/- 0.06).

Every hypertensive patient receiving treatment and available at participating facilities during data collection was approached to participate in this study. Patients were eligible if they self-reported hypertension diagnosis, had received treatment for a minimum of 6 months after diagnosis, and were more than 18 years of age. Consenting patients were selected based on meeting the eligibility criteria and the order of arrival at the clinic. Respondents were asked to report on their health service use, associated costs, income, and coping mechanisms if they undertook any of the following to meet hypertension care costs: borrowing (having taken a loan), selling household items or assets (eg, livestock), and use of savings.

2.3 | Measuring patient costs
Interviews were conducted using a structured questionnaire. Three trained interviewers collected the data. Interviews were conducted primarily in Kiswahili, with local languages (Giriama and Bukusu in Kilifi and Bungoma, respectively) used to clarify questions where necessary. Respondents were asked about costs incurred for different care seeking episodes described in Table 1.

To annuitize sick visit costs, we summed up costs incurred during current care visit and any reported outpatient visit costs that occurred due to hypertension in the last 4 weeks and then multiplied by 13 (assuming there are 52 weeks in a year). On the other hand, to annuitize costs in other care seeking episodes described in Table 1, reported costs were multiplied by the number of visits, ie, weekly, monthly, or quarterly for each episode. Furthermore, any inpatient admission costs in the last 1 year was also collected. Overall hypertension care costs for all care seeking episodes were calculated by summing up the annual costs in each care seeking episode.

For each of the care seeking episode, two broad costs categories were estimated: direct OOP costs and indirect (productivity losses) costs for both patients and their caregivers. Direct health care costs included any charges levied for medicines and user fees, ie, registration, consultation, and laboratory services. Direct non-health care costs
included transport costs to and from a health provider and any costs associated with food and accommodation while seeking care. For this descriptive analysis, OOP costs were defined as the sum of direct health care and direct non-health care costs. Analysis was restricted to patients who reported any OOP costs for each care seeking episode.

Indirect costs were estimated based on the total hours lost while seeking care as well as the cost of illness-related to lost home productivity for both patients and their caregivers, assuming that these hours would have been used for productive activity in the absence of hypertension.\(^{30}\) Income lost due to hypertension illness was therefore estimated by multiplying the estimated number of lost production hours due to hypertension by the official minimum wage (US$ 84 per month) in the agricultural sector in 2017 given the main economic activities in our study sites.\(^{31}\) We assumed an average workday of 8 hours per day and 22 working days per month. Caregivers’ lost home productivity was also estimated by multiplying the total number of hours spent by caregivers caring for the patient by the official minimum wage rate.

Income was estimated by asking detailed questions about income categories, including patient income, income for household members, welfare payments, and government assistance. As a measure of financial risk protection, we compared total direct costs incurred against annual household income and total direct costs excluding transport costs and defined costs as catastrophic if they exceeded 10% of household income.\(^{32}\)

### 2.4 Data management and analysis

Data were double-entered by two different individuals to enhance data quality. The two data sets were compared to eliminate data entry errors. Consistency and range checks were used to ensure completeness of data. Data were analysed using STATA 14.0 (STATA, Statacorp, Texas). Frequency counts and percentages were used to describe patient demographic and socio-economic variables. Due to skewed nature of costs data, mean and median values were reported for all cost estimates as a measure of central tendency, and 95% confidence intervals (CI) and inter-quartile range (IQR) were reported. Cost information (in Kenya shillings was converted to United States Dollars [US$] using the following exchange rate: US$ 1 = KES 102 (average exchange rate, January to December 2017; Currency Converter/Foreign Exchange Rates/OANDA. http://www.oanda.com/currency/ converter/).

### 3 RESULTS

#### 3.1 Participants characteristics and health services utilisation

In total, 212 individuals were interviewed, 114 (54%) from Kilifi. Less than half of the sampled patients had secondary level education, were formally employed, or were subscribed to a health insurance scheme (Table 2). More than 80%
of the patients were diagnosed with hypertension at a public facility and had been on treatment for at least 1 year (Table 2). The median travel time to a health facility was 30 minutes (IQR, 19-60). Ninety-one percent (95% CI, 86.3-94.2) of the respondents used public means of transport to get to the health facility while 9.0% (95% CI, 5.8-13.7) walked. Fifty-eighth patients reported that the facility they attended was not the nearest to them; of these, 43.1% (95% CI, 30.7-56.4) reported referral, 41.4% (95% CI, 29.2-54.7) reported lack of medicines and/or diagnostic facilities, and 15.5% (95% CI, 8.1-27.6) reported other reasons for not visiting the nearest health facility.

3.2 | Patient costs associated with health care use

3.2.1 | Sick visit costs

Thirty-six percent of the patients sought care outside of their scheduled clinic appointments. Transport costs during a sick visit represented the highest cost category (42.2%) of all direct OOP costs. Patients incurred substantial indirect costs (mean annual cost, US$ 113.5; 95% CI, 92.6-134.3) for such outpatient sick visits (Table 3).

### TABLE 2  Patient characteristics

| Characteristic               | (n) Observations | Proportion (95% CI) |
|------------------------------|------------------|---------------------|
| Mean age in years            | 212              | 60 (58.2-61.8)      |
| Gender                       |                  |                     |
| Male                         | (212) 50         | 23.6% (18.3-29.8)    |
| Female                       | (212) 162        | 76.4% (70.2-81.7)    |
| Highest education level      |                  |                     |
| None                         | (212) 61         | 28.8% (23.0-35.3)    |
| Primary                      | (212) 82         | 38.7% (32.3-45.5)    |
| Secondary                    | (212) 53         | 25.0% (19.6-31.3)    |
| Higher                       | (212) 16         | 7.5% (4.7-12.0)      |
| Enrolled to a health insurance scheme |           |                     |
| Yes                          | (212) 46         | 21.7% (16.6-27.8)    |
| No                           | (212) 166        | 78.3% (72.2-83.4)    |
| Employment status            |                  |                     |
| Formal employment            | (211) 42         | 19.9% (15.0-25.9)    |
| Informal/unemployed          | (211) 169        | 80.1% (74.1-85.0)    |
| Breadwinner                  |                  |                     |
| Patient                      | (211) 94         | 44.5% (37.9-51.4)    |
| Not patient                  | (211) 117        | 55.5% (48.6-62.1)    |
| Reason for not working       |                  |                     |
| Related to hypertension      | (208) 46         | 22.1% (17.0-28.3)    |
| Not related to hypertension  | (208) 162        | 77.9% (71.7-83.0)    |
| Where diagnosed              |                  |                     |
| Public facility              | (212) 186        | 87.7% (82.5-91.5)    |
| Private facility             | (212) 26         | 12.3% (8.5-17.5)     |
| Illness duration             |                  |                     |
| 6 mo-1 y                     | (212) 33         | 15.6% (11.3-21.1)    |
| 1-5 y                        | (212) 101        | 47.6% (40.9-54.4)    |
| >5 y                         | (212) 78         | 36.8% (30.5-43.5)    |
### TABLE 3  Mean and median annual hypertension care cost at five public facilities in Kenya (2017 US$)

| Care Seeking Episode | Cost Category              | Observations | Mean US$ (95% CI) | Median US$ (IQR) | As a % of Total Direct Costs |
|----------------------|----------------------------|--------------|-------------------|-----------------|-----------------------------|
| **Sick visit**       | Direct health care costs   |              |                   |                 |                             |
|                      | User charges               | 76           | 79.0 (49.2-108.8) | 31.2 (12.7-71.4) | 18.2                        |
|                      | Medicines                  | 76           | 140.8 (91.7-189.9) | 63.7 (17.5-175.9) | 38.3                        |
|                      | Direct non–health care costs |            |                   |                 |                             |
|                      | Transport                  | 76           | 173.9 (58.0-289.7) | 70.1 (25.5-152.9) | 42.2                        |
|                      | Food                       | 76           | 4.6 (0.9-8.2)     | 0               | 1.3                         |
|                      | Subtotal (direct costs)    | 76           | 398.2 (242.7-553.7) | 214.8 (89.9-470.3) |                             |
|                      | Indirect costs             | 76           | 113.5 (92.6-134.3) | 87.1 (55.4-136.9) |                             |
|                      | Direct + indirect costs    | 76           | 511.7 (348.2-672.5) | 327.9 (143.2-624.3) |                             |
| **In-patient admission** | Direct health care costs   |              |                   |                 |                             |
|                      | User charges               | 23           | 50.8 (25.1-76.5)  | 32.1 (9.8-63.7)  | 49.8                        |
|                      | Medicines                  | 22           | 24.0 (12.3-35.6)  | 16.6 (3.4-34.3)  | 22.5                        |
|                      | Direct non–health care costs |            |                   |                 |                             |
|                      | Transport                  | 26           | 14.1 (5.4-22.9)   | 5.9 (3.1-15.7)   | 15.7                        |
|                      | Food                       | 10           | 28.3 (3.3-53.3)   | 10.3 (7.8-54.9)  | 12.0                        |
|                      | Subtotal (direct costs)    | 26           | 90.3 (48.7-131.8) | 64.5 (19.8-102.0) |                             |
|                      | Indirect costs             | 26           | 67.2 (37.3-97.1)  | 31.2 (16.3-108.7) |                             |
|                      | Direct + indirect costs    | 26           | 157.5 (99.1-215.8) | 124.9 (46.3-231.6) |                             |
| **Medicine collection** | Direct health care costs   |              |                   |                 |                             |
|                      | Medicines                  | 152          | 37.4 (29.0-45.8)  | 20.6 (7.8-45.9)  | 75.2                        |
|                      | Direct non–health care costs |            |                   |                 |                             |
|                      | Transport                  | 43           | 36.4 (25.5-47.3)  | 23.5 (8.2-70.6)  | 20.7                        |
|                      | Food                       | 13           | 24.0 (7.3-40.6)   | 11.8 (8.8-23.5)  | 4.1                         |
|                      | Subtotal (direct costs)    | 163          | 46.4 (36.8-55.9)  | 23.5 (9.4-58.8)  |                             |
|                      | Indirect costs             | 212          | 38.8 (33.6-44.0)  | 29.1 (14.8-51.0) |                             |
|                      | Direct + indirect costs    | 212          | 157.5 (99.1-215.8) | 124.9 (46.3-231.6) |                             |
| **Diagnostic visit** | Direct health care costs   |              |                   |                 |                             |
|                      | Test                       | 30           | 9.3 (6.0-12.7)    | 6.5 (2.4-11.8)   | 14.4                        |
|                      | Direct non–health care costs |            |                   |                 |                             |
|                      | Transport                  | 38           | 36.1 (25.9-49.9)  | 23.5 (11.8-47.1) | 74.2                        |
|                      | Food                       | 9            | 24.4 (11.5-37.3)  | 23.5 (11.8-35.3) | 11.3                        |
|                      | Subtotal (direct costs)    | 61           | 31.8 (21.9-41.7)  | 14.1 (5.9-47.1)  |                             |
|                      | Indirect costs             | 202          | 33.2 (28.3-38.0)  | 23.4 (11.5-40.2) |                             |
|                      | Direct + indirect costs    | 202          | 42.6 (35.5-50.0)  | 28.7 (11.5-43.1) |                             |
| **Scheduled clinics** | Direct health care costs   |              |                   |                 |                             |
|                      | User charges               | 184          | 11.0 (9.0-13.1)   | 6.7 (3.1-11.8)   | 17.9                        |
|                      | Medicines                  | 145          | 35.9 (26.4-45.5)  | 16.5(5.9-38.4)   | 45.8                        |
|                      | Direct non–health care costs |            |                   |                 |                             |
|                      | Transport                  | 193          | 20.0 (16.0-24.0)  | 11.8 (7.1-23.5)  | 34.0                        |
|                      | Food                       | 14           | 19.1 (8.3-30.0)   | 11.8 (3.5-35.3)  | 2.3                         |
|                      | Subtotal (direct costs)    | 212          | 53.6 (43.3-63.9)  | 31.0 (14.1-61.2) |                             |
|                      | Indirect costs             | 212          | 31.3 (26.2-36.5)  | 23.0 (11.5-37.4) |                             |
|                      | Direct + indirect costs    | 212          | 84.9 (71.4-98.5)  | 54.6 (31.7-91.7) |                             |
| **Overall costs**    | Direct health care costs   |              |                   |                 |                             |
|                      | User charges               | 187          | 57.7 (43.7-71.6)  | 28.3 (16.7-55.9) | 16.7                        |
|                      | Medicines                  | 162          | 168.9 (132.5-205.4) | 84.3 (26.3-210.5) | 42.4                        |
|                      | Direct non–health care costs |            |                   |                 |                             |
|                      | Transport                  | 196          | 126.7 (77.6-175.9) | 58.8 (24.5-128.4) | 38.4                        |
|                      | Food                       | 31           | 46.3 (28.3-64.4)  | 27.0 (8.9-72.5)  | 2.2                         |
|                      | Subtotal (direct costs)    | 212          | 304.8 (235.7-374.0) | 141.3 (70.0-327.0) |                             |
|                      | Indirect costs             | 212          | 171.7 (152.8-190.5) | 141.4 (80.1-209.9) |                             |
|                      | Direct + indirect costs    | 212          | 476.5 (397.8-555.2) | 282.7 (183.2-552.9) |                             |

Abbreviations: CI, confidence interval; IQR, interquartile range.

aData include accommodation costs.
3.2.2 | Inpatient costs

The median number of hypertension-related admissions the year preceding data collection was one with each inpatient admission lasting a median of four days (IQR, 2-8). Of the total direct costs, user charges—especially during an inpatient admission—were a substantial cost compared with other care seeking episodes, with respondents spending an average of US$ 50.8 per annum. This was followed by food and/or accommodation costs (mean annual cost, US$ 28.3; 95% CI, 3.3-53.3) (Table 3). Not surprisingly, indirect costs (mean annual cost, US$ 67.2; 95% CI, 37.3-97.1) for an inpatient admission were high compared with direct costs.

3.2.3 | Medicine collection costs

Most patients incurred costs on monotherapy or two-drug regimens at the time of interview (Table 4). Enalapril and hydrochlorothiazide was the most expensive combination of all prescribed antihypertensive medicines attracting mean annual cost of US$ 43.7 (95% CI, 29.2-58.3) (Table 4). On the other hand, slightly more than half (57.1%) of the patients reported obtaining their routine medicines from a public hospital (Figure 1). Medicines accounted for 75.2% of total OOP costs during a medicine collection visit while transport and food accounted for 20.7% and 4.1%, respectively (Table 3).

3.2.4 | Diagnostic/laboratory test costs

The main routine diagnostic test for hypertensive patients was blood pressure and weight (mean annual cost, US$ 1.2; 95% CI, 0.3-2.0). Diagnostic costs were likely low given that blood pressure and weight are checked for free at public health care facilities. Other reported tests were blood pressure (annual mean cost, US$ 1.3; 95% CI, 0.4-2.2) and urinalysis and echocardiogram (annual mean cost, US$ 4.5; 95% CI, 1.8-10.7). The mean annual direct cost for seeking diagnostic or laboratory test services was US$ 31.8 (95% CI, 21.9-41.7) with transport costs accounting for 74.2% of total OOP costs (Table 3).

3.2.5 | Scheduled clinic appointment costs

Half (52.8%) of the respondents attended their routine clinics monthly. The highest direct cost category during scheduled clinic appointments was medicines accounting for 45.8% of total OOP costs followed by transport (34%), user charges (17.9%), and food (2.3%) (Table 3).

TABLE 4 | Drug combination costs

| Drug Name                      | Observation | Mean US$ (95% CI) | Median US$ (IQR) |
|--------------------------------|-------------|------------------|------------------|
| Enalapril                      | 11          | 37.6 (18.8-56.3) | 47.1 (10.6-56.5) |
| Hydrochlorothiazide            | 19          | 25.9 (14.2-37.6) | 21.2 (4.7-47.1)  |
| Nifedipine                     | 51          | 31.7 (20.0-43.5) | 13.5 (3.9-52.9)  |
| Enalapril + hydrochlorothiazide| 24          | 43.7 (29.2-58.3) | 40.6 (18.2-61.8) |
| Nifedipine + enalapril         | 10          | 16.2 (6.3-26.0)  | 10.6 (3.1-22.7)  |
| Nifedipine + hydrochlorothiazide| 47          | 28.8 (17.6-39.9) | 17.6 (7.8-33.5)  |
| Nifedipine + hydrochlorothiazide + enalapril | 10 | 36.6 (5.3-68.0) | 16.8 (7.1-42.4) |
| Other combinations*            | 10          | 29.5 (15.7-43.4) | 30.6 (12.9-38.2) |

Abbreviations: CI, confidence interval; IQR, interquartile range.

Asterisk is used to describe "Other combinations" as indicated: * Aminosaliysilic Acid + Atorvastatin = 1; Aminosaliysilic Acid + Losartan = 1; Amlodipine + Aminosaliysilic Acid + Digoxin = 1; Methyldopa = 1; Amlodipine + Amitriptyline = 1; Atenolol= 1; Losartan + Atenolol = 1; Losartan = 1; Unknown = 2
Overall hypertension care costs

Overall, the average direct annual costs for all hypertension care seeking episodes was US$ 304.8 (95% CI, 235.7-374.0). Under direct costs, medicines (mean annual cost, US$ 168.9; 95% CI, 132.5-205.4) attracted the largest share of costs (42.4%) followed by transport (mean annual cost, US$ 126.7; 95% CI, 77.6-175.9), which represented 38.4% of total patient costs. User charges (mean annual cost, US$ 57.7; 95% CI, 43.7-71.6), food (mean annual cost, US$ 46.3; 95% CI, 28.3-64.4), and accommodation (mean annual cost, US$ 27.8; 95% CI, 4.4-60.0) accounted for 16.7%, 2.2%, and 0.3% of total direct costs, respectively (Table 3). The overall mean indirect annual costs due to hypertension care seeking was US$ 171.7 (95% CI, 152.8-190.5).

Impact on household income and coping strategies

Costs for hypertension services were catastrophic for more than half (59%; 95% CI, 52.2-65.4) of the households if all direct costs were considered. Alternatively, 43.3% (95% CI, 36.8-50.2) of households experienced catastrophe if transport costs were excluded. Among respondents experiencing catastrophic costs, the poorest group of patients incurred higher direct costs with fewer resources to pay for it (Figure 2). The study found that most of the patients were unable to pay for hypertension treatment from their existing income sources and had to rely on savings (43.9%), borrowing from family/friends (25.1%), or sale of assets (31%), of which 33.3% was livestock. None of the hypertension patients reported receiving reimbursement for OOP costs incurred from either an insurance company or employer when seeking care for hypertension.

Figure 1: Source of hypertension medicines

Figure 2: Relationship between catastrophic costs and socio-economic status (Social-economic status is represented by wealth quintiles: Quintile 1 represents the lowest socio-economic group, while 5 represents the highest)
3.4 | Productivity and social impact of hypertension

Patients were asked to estimate the number of work days they missed in the last 3 months due to hypertension. Of the 212 respondents, 30% reported they missed a median of 17 (IQR, 6-46) working days. Forty-two percent of respondents reported disrupted social life due to hypertension, affecting sexual life (n = 27), job loss (n = 46), divorce (n = 5), and separation from spouse (n = 10).

4 | DISCUSSION

This study has documented patient costs for adults with hypertension that sought care in five public health care facilities in Kenya. Our findings show that patients cost for hypertension are driven by medicines. This is particularly worrisome given that unaffordability of hypertensive medicines is a likely cause of uncontrolled hypertension. Consequently, this is likely to interfere with continuity and comprehensiveness of care as patients only seek care when they have access to funds. About half (57.7%) of the hypertensive patients reported they obtained their medicines from a public hospital. This suggests the possibility of infrequent antihypertensive drug supply in the sampled facilities. Medicines availability is a major factor influencing health care seeking behaviour. Strategies to strengthen and expand access programmes to improve the availability of medicines for chronic diseases including antihypertensive medicines should be implemented to address such deficiencies. Additionally, health being a devolved function in Kenya, county governments should develop mechanisms to ensure regular supply of antihypertensive medicines in public facilities and more generally improve financial access to these medicines.

Patients reported a median time of 30 minutes to access the clinics either by public means of transport or by walking; the cost of travelling to the medical clinics for different care seeking episodes was found to be a significant driver of patient costs. For instance, while the incidence of catastrophic health care costs was 43.3% (95% CI, 36.8-50.2), it increased to 59.0% (95% CI, 52.2-65.4) when transport costs were included. This could have negative access effects especially on poor patients as high transport costs and long distance to health facilities have been shown to hinder the poor from benefiting in pro-poor health financing reforms in Kenya.

A high number of patients (36%) reported a sick visit out of their scheduled clinic appointment. This indicates that poor management of hypertension impacts both the health and the economic burden for patients as evidenced by high costs on transport (mean annual cost, US$ 173.9; 95% CI, 173.9-289.7) and medication (mean annual cost, US$ 140.8; 95% CI, 131.7-189.9). In addition, high user charges seen in all care seeking episodes, particularly during an inpatient admission, are potential barriers to care seeking given that the negative impacts of user charges in low resource settings, which have been well documented. There is substantial variation in patient costs between the inpatient and outpatient care seeking episodes. Inpatient admission costs represent a substantial economic burden.

Patients had to sell their property in order to meet associated costs of hypertension management in keeping with other assessment of the impact of health expenditures on households. The fact that about 36.1% of the Kenyan population live below the national poverty line indicates that patients are unable to meet treatment-related expenditure for hypertension and had to adopt negative coping strategies such as borrowing or relying on family or social networks for assistance. One of the interventions for achieving the UHC goal of financial risk protection being pursued in Kenya and other LMICs is expansion of coverage under prepayment schemes such as social health insurance. Our results show that three quarters of sampled hypertensive patients were not subscribed to any health insurance scheme reflecting coverage levels at a national level in Kenya where 80% of the population are not covered by any health insurance scheme. This is similar to findings made by Kankeu et al in a review of financial burden of NCDs in LMICs. This means that hypertensive patients, especially those belonging to the lower rungs of the income ladder, bear a disproportionately higher burden of OOP, hence making them certain candidates to “medical poverty trap” where poor patients have to cope with the effect of reduced disposable income for other consumptions, which in turn increases poverty.
High indirect costs (in terms of waiting time and the resultant productivity hours lost) were reported in this study during care seeking episodes. This is common in public health facilities and has been identified as a major disincentive of seeking care in public facilities among employed hypertensive patients in South Africa.51

4.1 Limitations

This study had several limitations. First, the study was not nationally representative as it was carried out in five health facilities in two rural counties. Secondly, the use of an official minimum wage to estimate productivity loss for all patients could have potentially overestimated indirect costs among patients who were unemployed prior to their illness or underestimated indirect costs among those who were employed.30 Recall bias is a concern in patient cost surveys. The study only focused on OOP costs associated with seeking care and does not include costs associated with those who did not seek care. These costs would be important in giving a comprehensive picture of OOP health care costs associated with hypertension care. These limitations notwithstanding, the data presented are potentially useful as inputs in costing and/or cost-effectiveness models that require patient cost and suggest there are significant OOP costs associated with hypertension management in public facilities in Kenya, which offer a barrier to access to care.

5 CONCLUSION

The study demonstrates that hypertension places a considerable economic burden on patients in Kenya. As Kenya reforms its health system to prioritize the attainment of UHC, our results suggest that there is need for interventions to provide financial risk protection to individuals with a chronic disease such as hypertension. Given that medicines are a key cost driver for patient out-of-pocket costs, one approach would be to explicitly include hypertension medicines in the universal health care benefit package that Kenyan citizens are entitled to.

ETHICS STATEMENTS

The scientific and ethics review unit at Kenya Medical Research Institute (KEMRI/SERU/CGMR-C/041/3270) granted ethical approval for the study. County department of health officials and facility managers in respective counties provided permission to conduct the study in the selected facilities, and written informed consent was obtained from respondents.

AVAILABILITY OF DATA AND MATERIAL

All the data for this study are available, and it can be accessed at the KEMRI-Wellcome Trust Research Programme, subject to institutional data governance committee policies.

ACKNOWLEDGEMENTS

This work is published with the permission of the Director of the Kenya Medical Research Institute (KEMRI).

This work is funded by a KEMRI Internal Research Grant (IRG-04) awarded to Anthony Etyang. Additional funds from a Wellcome Trust Research Training Fellowship (107527) awarded to Edwine Barasa, a Wellcome Trust International Master's Fellowship (214622) awarded to Robinson Oyando, and a Wellcome Trust core grant (092654) awarded to the KEMRI-Wellcome Trust Research Program supported this work.

The authors declare that they have no competing interests.
AUTHOR CONTRIBUTIONS

Edwine Barasa, Anthony Etyang, Kenneth Munge, Jane Mbui, Zipporah Bukania, Fredrick Kirui, and Andrew Obala conceived the study. Robinson Oyando, Martin Njoroge, Antipa Sigilai, Kenneth Munge, Peter Nguhiu, and Edwine Barasa contributed to the development of data collection tools. Robinson Oyando collected the data. Robinson Oyando and Edwine Barasa analysed the data. Robinson Oyando developed the first draft of the manuscript. All authors contributed to writing subsequent versions of the manuscript.

ORCID

Robinson Oyando https://orcid.org/0000-0001-8768-6014

REFERENCES

1. United Nations. Sustainable development goals: 17 goals to transform our world. 2015.
2. World Health Organization. Tracking universal health coverage: first global monitoring report. World Health Organization: Geneva; 2015.
3. Foster N, Vassall A, Cleary S, Cunnama L, Churchyard G, Sinanovic E. The economic burden of TB diagnosis and treatment in South Africa. Soc Sci Med. 2015;130:42-50.
4. Bloom DE, Chisholm D, Jané-Llopis E, Prettkner K, Stein A, Feigl A. From burden to “best buys”: reducing the economic impact of non-communicable disease in low- and middle-income countries. Program on the Global Demography of Aging; 2011.
5. Kankeu HT, Saksena P, Xu K, Evans DB. The financial burden from non-communicable diseases in low- and middle-income countries: a literature review. Health Res Policy Syst. 2013;11(1):31.
6. Ministry of Health. Kenya STEPwise survey for non-communicable diseases risk factors 2015 report. Nairobi: Kenya; 2015.
7. Awoke A, Awoke T, Alemu S, Megabiaw B. Prevalence and associated factors of hypertension among adults in Gondar, Northwest Ethiopia: a community based cross-sectional study. BMC Cardiovasc Disord. 2012;12(1):113.
8. Kenya Institute for Public Policy Research. Realizing the “Big Four Agenda” through energy as an enabler. Issue 9 No. 3 March 2018.
9. Chuma J, Okungu V. Viewing the Kenyan health system through an equity lens: implications for universal coverage. Int J Equity Health. 2011;10(1):22.
10. Barasa E, Nguhiu P, McIntyre D. Measuring progress towards Sustainable Development Goal 3.8 on universal health coverage in Kenya. BMJ glob health. 2018;3(3):e000904.
11. McIntyre D, Obse A, Barasa E. Challenges in financing universal health coverage in sub-Saharan Africa. In: Oxford Research Encyclopedia of Economics and Finance; 2018, Oxford University Press USA: Oxford.
12. Mbu R, Barasa E, Munge K, Mulupi S, Ng’udi PK, Chuma J. A critical analysis of health care purchasing arrangements in Kenya: a case study of the county departments of health. Int J Health Plann Manag. 2018;33(4):1159-1177.
13. Mulupi S, Kirigia D, Chuma J. Community perceptions of health insurance and their preferred design features: implications for the design of universal health coverage reforms in Kenya. BMC Health Serv Res. 2013;13(1):474.
14. Munge K, Briggs AH. The progressivity of health-care financing in Kenya. Health Policy Plann. 2013;29(7):912-920.
15. Chuma J, Maina T. Catastrophic health care spending and impoverishment in Kenya. BMC Health Serv Res. 2012;12(1):413.
16. Barasa EW, Maina T, Ravishankar N. Assessing the impoverishing effects, and factors associated with the incidence of catastrophic health care payments in Kenya. Int J Equity Health. 2017;16(1):31.
17. Kazungu JS, Barasa EW. Examining levels, distribution and correlates of health insurance coverage in Kenya. Tropical Med Int Health. 2017;22(9):1175-1185.
18. Subramanian S, Gakunga R, Kibachio J, et al. Cost and affordability of non-communicable disease screening, diagnosis and treatment in Kenya: patient payments in the private and public sectors. PloS One. 2018;13(1):e0190113.
19. KNBS. Kenya demographic and health survey 2014.2014.
20. Mathenge W, Foster A, Kuper H. Urbanization, ethnicity and cardiovascular risk in a population in transition in Nakuru, Kenya: a population-based survey. BMC Public Health. 2010;10(1):569.
21. Van de Vijver SJ, Oti SO, Agyemang C, Gomez GB, Kyobutungi C. Prevalence, awareness, treatment and control of hypertension among slum dwellers in Nairobi, Kenya. J Hypertens. 2013;31(5):1018-1024.

22. Murphy A, Jakab M, McKee M, Richardson E. Persistent low adherence to hypertension treatment in Kyrgyzstan: how can we understand the role of drug affordability? Health Policy Plann. 2016;31(10):1384-1390.

23. MacMahon S, Alderman MH, Lindholm LH, Liu L, Sanchez RA, Seedat YK. Blood-pressure-related disease is a global health priority. Am J Hypertens. 2008;21(8):843-844.

24. Etyang AO, Munge K, Bunyasi EW, et al. Burden of disease in adults admitted to hospital in a rural region of coastal Kenya: an analysis of data from linked clinical and demographic surveillance systems. Lancet Glob Health. 2014;2(4):e216-e224.

25. Scott JAG, Bauni E, Moisi JC, et al. Profile: the Kilifi health and demographic surveillance system (KHDSS). International Journal of Epidemiology. 2012;41(3):650-657.

26. Simiyu C, Naanyu V, Obala A, Odhiambo DO, Ayoo P, Chelagat D, Downing R, Menya D, Mwaliko E, O'Meara WP,Were EO. Establishing Webuye Health and Demographic Surveillance Site in rural western Kenya: challenges and lessons learned. Paper presented at: Population Association of America Annual Meeting Problem 2013.

27. Bloomfield GS, Mwangi A, Chege P, et al. Multiple cardiovascular risk factors in Kenya: evidence from a health and demographic surveillance system using the WHO STEPSwise approach to chronic disease risk factor surveillance. Heart. 2013;heartjnl-2013-303913;99(18):1323-1329.

28. Irimu G, Ogero M, Mbevi G, et al. Tackling health professionals’ strikes: an essential part of health system strengthening in Kenya. BMJ Glob Health. 2018;3(6):e001136.

29. Kirkwood BR, Sterne JA. Essential Medical Statistics. John Wiley & Sons: Malden, Massachuesetts, USA; 2010.

30. Ramma L, Cox H, Wilkinson L, et al. Patients’ costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis. 2015;19(12):1513-1519.

31. KNBS. Kenya economic survey 2018. 2018.

32. Wagstaff A, Flores G, Hsu J, et al. Progress on catastrophic health spending in 133 countries: a retrospective observational study. Lancet Glob Health. 2018;6(2):e169-e179.

33. Attaei MW, Khatib R, McKee M, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health. 2017;2(9):e411-e419.

34. Bovet P, Gervasoni J-P, Mkamba M, Balampama M, Lengeler C, Paccaud F. Low utilization of health care services following screening for hypertension in Dar es Salaam (Tanzania): a prospective population-based study. BMC Public Health. 2008;8(1):407.

35. Pradeepa R. The rising burden of diabetes and hypertension in Southeast Asian and African regions: need for effective strategies for prevention and control in primary health care settings. International Journal of Hypertension. 2013;2013:5-15.

36. Mbwij JM, Oluka MN, Guantai EM, et al. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Rev Clin Pharmacol. 2017;10(11):1263-1271.

37. Goudge J, Gilson L, Russell S, Gumede T, Mills A. Affordability, availability and acceptability barriers to health care for the chronically ill: longitudinal case studies from South Africa. BMC Health Serv Res. 2009;9(1):75.

38. Ukwaja KN, Alobu I, Abimbola S, Hopewell PC. Household catastrophic payments for tuberculosis care in Nigeria: incidence, determinants, and policy implications for universal health coverage. Infect Dis Poverty. 2013;2(1):21.

39. Chawla M, Ellis RP. The impact of financing and quality changes on health care demand in Niger. Health Policy Plann. 2000;15(1):76-84.

40. Chuma J, Gilson L, Molyneux C. Treatment-seeking behaviour, cost burdens and coping strategies among rural and urban households in Coastal Kenya: an equity analysis. Tropical Med Int Health. 2007;12(5):673-686.

41. McPake B, Hanson K, Mills A. Community financing of health care in Africa: an evaluation of the Bamako initiative. Soc Sci Med. 1993;36(11):1383-1395.

42. Novartis. Novartis Access uses portfolio approach to address affordability for products for non-communicable diseases. Available at URL: https://access2medicinefoundation.org/access-to-medicine-index/best-innovative-practices-novartis-access-uses-portfolio-approach-to-address-affordability-for-products-for-non-communicable-diseases (Accessed on 28 November 2018). 2018.

43. Ogola E. Health heart Africa—the Kenyan experience. 2015.
44. Kabia E, Mbau R, Oyando R, et al. We are called the et cetera*: experiences of the poor with health financing reforms that target them in Kenya 2018 (Forthcoming).

45. Chuma J, Musimbi J, Okungu V, Goodman C, Molyneux C. Reducing user fees for primary health care in Kenya: policy on paper or policy in practice? Int J Equity Health. 2009;8(1):15.

46. Kenya F. Kenya financial diaries Shilingi Kwa Shilingi—the financial lives of the poor. Nairobi: FSD Kenya, August http://www.fsdkenya.org/pdf_documents/14-08-08_Financial_Diaries_report.pdf. 2014.

47. KNBS. Kenya integrated household budget survey 2017.

48. Lagomarsino G, Garabrant A, Adyas A, Muga R, Otoo N. Moving towards universal health coverage: health insurance reforms in nine developing countries in Africa and Asia. The Lancet. 2012;380(9845):933-943.

49. McIntyre D. Learning from experience: health care financing in low-and middle-income countries. 2007.

50. Han W. Health care system reforms in developing countries. J Public Health Res. 2012;1(3):199.

51. Rayner B, Blockman M, Baines D, Trinder Y. A survey of hypertensive practices at two community health centres in Cape Town. S Afr Med J. 2007;97(4):280-281.

How to cite this article: Oyando R, Njoroge M, Nguhiu P, et al. Patient costs of hypertension care in public health care facilities in Kenya. Int J Health Plann Mgmt. 2019;34:e1166–e1178. https://doi.org/10.1002/hpm.2752